Alfonso Savastano1,2, Alice Bitossi3, Fabrizio Giansanti3, Lorenzo Vannozzi3, Tomaso Caporossi3, Francesco Barca3, Gianni Virgili3, Gloria Gambini4, Umberto De Vico4, Patrizio Bernardinelli4,5, Maria Cristina Savastano4,5, Stanislao Rizzo4,5,6. 1. Unit of Ophthalmology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168, Rome, Italy. alfonso.savastano@policlinicogemelli.itm. 2. Catholic University of "Sacro Cuore", Rome, Italy. alfonso.savastano@policlinicogemelli.itm. 3. Department of Surgery and Translational Medicine, Eye Clinic, University of Florence, Florence, Italy. 4. Unit of Ophthalmology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168, Rome, Italy. 5. Catholic University of "Sacro Cuore", Rome, Italy. 6. Consiglio Nazionale della Ricerca (CNR), Istituto di Neuroscienze, Pisa, Italy.
Abstract
PURPOSE: To evaluate the efficacy of intraoperative slow-release dexamethasone implant (DEX) combined with removal of idiopathic epiretinal membrane (ERM). METHODS: In this observational retrospective study, data of 40 patients with phakic eyes affected by idiopathic ERM were analysed. All patients underwent cataract phacoemulsification, 25-gauge (G) pars plana vitrectomy (PPV), ERM removal with DEX implant ("DEX YES" group, #20) or without DEX implant ("DEX NO" group, #20). We collected data on best-corrected visual acuity (BCVA) < 20/40 Snellen charts, central macular thickness (CMT) ≤ 400 μm (measured by SD-OCT) and integrity of sub-foveal ellipsoid/myoid zone. BCVA, CMT and intraocular pressure (IOP) were evaluated at baseline as well as 15, 30 and 90 days after surgery. RESULTS: In the "DEX YES" group, statistically significant BCVA improvement was observed at 15, 30 and 90 days (p < 0.001), while in the "DEX NO" group, improvements were observed only at 30 and 90 days (p < 0.001). In both groups, CMT significantly decreased at each follow-up visit (p < 0.001), and no statistically significant increase of IOP was detected at each follow-up visit. CONCLUSIONS: In this study, DEX accelerated the improvement of BCVA at 15 days after surgery. However, no evidence of further anatomical (CMT) and functional (BCVA) DEX effectiveness combined with removal of idiopathic ERM by 25-G PPV at 30 and 90 days follow-up was observed.
PURPOSE: To evaluate the efficacy of intraoperative slow-release dexamethasone implant (DEX) combined with removal of idiopathic epiretinal membrane (ERM). METHODS: In this observational retrospective study, data of 40 patients with phakic eyes affected by idiopathic ERM were analysed. All patients underwent cataract phacoemulsification, 25-gauge (G) pars plana vitrectomy (PPV), ERM removal with DEX implant ("DEX YES" group, #20) or without DEX implant ("DEX NO" group, #20). We collected data on best-corrected visual acuity (BCVA) < 20/40 Snellen charts, central macular thickness (CMT) ≤ 400 μm (measured by SD-OCT) and integrity of sub-foveal ellipsoid/myoid zone. BCVA, CMT and intraocular pressure (IOP) were evaluated at baseline as well as 15, 30 and 90 days after surgery. RESULTS: In the "DEX YES" group, statistically significant BCVA improvement was observed at 15, 30 and 90 days (p < 0.001), while in the "DEX NO" group, improvements were observed only at 30 and 90 days (p < 0.001). In both groups, CMT significantly decreased at each follow-up visit (p < 0.001), and no statistically significant increase of IOP was detected at each follow-up visit. CONCLUSIONS: In this study, DEX accelerated the improvement of BCVA at 15 days after surgery. However, no evidence of further anatomical (CMT) and functional (BCVA) DEX effectiveness combined with removal of idiopathic ERM by 25-G PPV at 30 and 90 days follow-up was observed.
Authors: Hideki Koizumi; Richard F Spaide; Yale L Fisher; K Bailey Freund; James M Klancnik; Lawrence A Yannuzzi Journal: Am J Ophthalmol Date: 2008-01-11 Impact factor: 5.258
Authors: Ning Cheung; Shu-Pei Tan; Shu Yen Lee; Gemmy Chui Ming Cheung; Gavin Tan; Neelam Kumar; Ching-Yu Cheng; Tien Yin Wong Journal: Br J Ophthalmol Date: 2016-06-24 Impact factor: 4.638
Authors: Mario R Romano; Chiara Comune; Mariantonia Ferrara; Gilda Cennamo; Stefano De Cillà; Lisa Toto; Giovanni Cennamo Journal: J Ophthalmol Date: 2015-09-03 Impact factor: 1.909
Authors: Matteo Fallico; Andrea Maugeri; Giovanni L Romano; Claudio Bucolo; Antonio Longo; Vincenza Bonfiglio; Andrea Russo; Teresio Avitabile; Martina Barchitta; Antonella Agodi; Francesco Pignatelli; Paola Marolo; Luca Ventre; Guglielmo Parisi; Michele Reibaldi Journal: Front Pharmacol Date: 2021-04-15 Impact factor: 5.810